{"document_type": "article", "byline": {"contributor": "", "person": [{"role": "reported", "firstname": "Chad", "organization": "", "rank": 1, "lastname": "BRAY"}], "original": "By CHAD BRAY"}, "news_desk": "Business", "slideshow_credits": null, "abstract": null, "multimedia": [], "headline": {"main": "Jazz Pharmaceuticals to Buy Celator for $1.5 Billion"}, "print_page": null, "keywords": [{"value": "Mergers, Acquisitions and Divestitures", "is_major": "N", "rank": "1", "name": "subject"}, {"value": "Drugs (Pharmaceuticals)", "is_major": "N", "rank": "2", "name": "subject"}, {"value": "Jazz Pharmaceuticals Inc", "is_major": "N", "rank": "3", "name": "organizations"}], "snippet": "The deal would further bolster Jazz\u2019s portfolio by acquiring the maker of Vyxeos, a treatment for a form of leukemia.", "source": "The New York Times", "lead_paragraph": "The deal would further bolster Jazz\u2019s portfolio by acquiring the maker of Vyxeos, a treatment for a form of leukemia.", "word_count": "454", "pub_date": "2016-06-01T00:00:00Z", "subsection_name": "DealBook", "blog": [], "type_of_material": "News", "section_name": "Business Day", "web_url": "http://www.nytimes.com/2016/06/01/business/dealbook/jazz-pharmaceuticals-buy-celator-leukemia.html", "_id": "574d588738f0d826276782e3"}